文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

艾司洛尔与兰地洛尔对成人脓毒症患者死亡率影响的比较:系统评价与网状Meta分析

Comparison of Esmolol Versus Landiolol on Mortality in Adult Patients With Sepsis: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Crit Care Med · 2025-11-25
一句话结论在脓毒症成人患者中,与标准治疗相比,艾司洛尔可能降低28天死亡率(RR 0.69,95%CI 0.56-0.85,中等确定性),而兰地洛尔的作用因证据确定性低仍不确定。

该系统评价与网状Meta分析检索了截至2025年4月15日的五个数据库、注册库及参考文献,纳入10项在ICU进行的随机对照试验,共1035例成人脓毒症或脓毒性休克患者,比较艾司洛尔、兰地洛尔与标准治疗(SOC)对死亡率的影响。与SOC相比,艾司洛尔显著降低28天死亡率(RR 0.69,95%CI 0.56-0.85,中等确定性)和24小时心率(MD -16.92次/分,95%CI -23.49至-10.36,中等确定性);与SOC相比,兰地洛尔增加去甲肾上腺素用量(MD 0.09 μg/kg/min,95%CI 0.01-0.18,中等确定性)。与艾司洛尔相比,兰地洛尔与28天死亡率升高(RR 1.57,95%CI 1.08-2.30,低确定性)和去甲肾上腺素需求更高(MD 0.17 μg/kg/min,95%CI 0.02-0.32,低确定性)相关。作者认为艾司洛尔可能较SOC改善临床结局,兰地洛尔的作用因证据确定性低仍不确定,艾司洛尔相对兰地洛尔可能具有临床优势,但需进一步研究证实。

要点

  • 在脓毒症成人患者中,与标准治疗相比,艾司洛尔降低28天死亡率(RR 0.69,95%CI 0.56-0.85,中等确定性)。
  • 与艾司洛尔相比,兰地洛尔与28天死亡率升高相关(RR 1.57,95%CI 1.08-2.30,低确定性)。
  • 与艾司洛尔相比,兰地洛尔与去甲肾上腺素需求更高相关(MD 0.17 μg/kg/min,95%CI 0.02-0.32,低确定性)。
  • 与标准治疗相比,兰地洛尔增加去甲肾上腺素用量(MD 0.09 μg/kg/min,95%CI 0.01-0.18,中等确定性)。
  • 与标准治疗相比,艾司洛尔降低24小时心率(MD -16.92次/分,95%CI -23.49至-10.36,中等确定性)。

适用人群与场景

  • 纳入标准:随机对照试验, enrolled 年龄≥18岁、诊断为脓毒症或脓毒性休克、在ICU接受β受体阻滞剂治疗的患者。

研究设计与关键结果

  • 研究类型:系统评价与网状Meta分析;共纳入10项随机对照试验,1035例患者;检索截至2025年4月15日。
  • 与标准治疗相比,艾司洛尔降低28天死亡率(RR 0.69,95%CI 0.56-0.85,中等确定性)和24小时心率(MD -16.92次/分,95%CI -23.49至-10.36,中等确定性)。
  • 与标准治疗相比,兰地洛尔增加去甲肾上腺素用量(MD 0.09 μg/kg/min,95%CI 0.01-0.18,中等确定性)。
  • 与艾司洛尔相比,兰地洛尔与28天死亡率升高(RR 1.57,95%CI 1.08-2.30,低确定性)和去甲肾上腺素需求更高(MD 0.17 μg/kg/min,95%CI 0.02-0.32,低确定性)相关。

证据类型、等级与局限

  • 证据类型:系统评价与网状Meta分析;证据确定性采用GRADE分级,艾司洛尔对比标准治疗的28天死亡率和24小时心率为中等确定性,兰地洛尔对比标准治疗的去甲肾上腺素用量为中等确定性,兰地洛尔对比艾司洛尔的28天死亡率和去甲肾上腺素需求为低确定性。
  • 局限:作者指出兰地洛尔的作用因证据确定性低仍不确定,艾司洛尔相对兰地洛尔的临床优势需进一步研究证实并阐明机制。

对床旁实践的改变

  • 作者认为,在脓毒症成人患者中,艾司洛尔可能较标准治疗改善临床结局;兰地洛尔的作用因证据确定性低仍不确定;艾司洛尔相对兰地洛尔可能具有临床优势,但需进一步研究证实。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: The clinical efficacy of short-acting β-blockers in the management of sepsis remains uncertain. In particular, the comparative effects of two commonly used agents-esmolol and landiolol-have not been clearly established. This network meta-analysis aims to systematically evaluate and compare the effects of esmolol, landiolol, and standard of care (SOC) on mortality in patients with sepsis.

DATA SOURCES: A systematic search of PubMed, Web of Science, Embase, MEDLINE, CENTRAL, ClinicalTrials.gov , preprints, and citation searching was conducted before April 15, 2025.

STUDY SELECTION: Randomized controlled trials that enrolled adult patients (≥ 18 yr) diagnosed with sepsis or septic shock and treated with β-blockers and conducted in ICUs.

DATA EXTRACTION: Data were extracted on study characteristics, enrolled patients' characteristics, administration strategies of drugs, and key clinical outcomes (including 28-d mortality, ICU length of stay, and other relevant endpoints).

DATA SYNTHESIS: A total of 1165 records were identified through searches of five databases, registries, and relevant references up to April 15, 2025. Ten studies involving 1035 patients were included, after screening and eligibility assessment. Compared with esmolol, landiolol was associated with increased 28-day mortality (relative risk [RR], 1.57; 95% CI, 1.08-2.30; low certainty) and higher norepinephrine requirements (mean difference [MD], 0.17 μg/kg/min; 95% CI, 0.02-0.32; low certainty). Esmolol significantly reduced 28-day mortality (RR, 0.69; 95% CI, 0.56-0.85; moderate certainty) and 24-hour heart rate (MD, -16.92 beats/min; 95% CI, -23.49 to -10.36; moderate certainty) compared with SOC. In contrast, landiolol increased norepinephrine use compared with SOC (MD, 0.09 μg/kg/min; 95% CI, 0.01-0.18; moderate certainty).

CONCLUSIONS: Among patients with sepsis treated with β-blockers, esmolol probably improves clinical outcomes compared with SOC. However, the effect of landiolol remains uncertain due to the low certainty of evidence. Esmolol may confer a relative clinical advantage over landiolol, but further studies are needed to confirm this finding and elucidate the underlying mechanisms.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Tang Z, Sun Q, Xu J, et al. Comparison of Esmolol Versus Landiolol on Mortality in Adult Patients With Sepsis: A Systematic Review and Network Meta-Analysis. Crit Care Med. 2025. PMID: 41363997. doi:10.1097/CCM.0000000000006966

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。